Systemic adaptive immune response to live attenuated measles, mumps, rubella, and yellow fever vaccine antigens

The systemic adaptive immune response to live attenuated measles, mumps, rubella, and yellow fever vaccine antigens is a complex physiological process rather than a single molecular target. This response is characterized by the activation of the host's adaptive immune system following the administration of weakened viral strains, which mimic natural infection without causing severe disease (CDC, 2021). The process involves the recognition of viral epitopes by T-cell receptors (TCR) and B-cell receptors (BCR), leading to the generation of high-titer neutralizing antibodies and polyfunctional T-cell responses (Pulendran et al., 2013, Nature Immunology). Specifically, the yellow fever vaccine (YF-17D) is considered a gold standard in vaccinology for its ability to induce broad, long-lasting CD8+ T-cell memory (Akondy et al., 2009, Journal of Immunology). The MMR vaccine components primarily drive the production of antibodies essential for herd immunity against measles, mumps, and rubella viruses (WHO, 2023). Monitoring this response is critical for assessing vaccine efficacy and safety, particularly in vulnerable populations where live vaccines may pose a risk of uncontrolled viral replication.

Other names

Adaptive immunity to MMR and YF vaccinesVaccine-induced systemic immune responseHumoral and cellular response to live-attenuated viral vaccines

Induction of long-term humoral and cellular immunity through the presentation of viral antigens by MHC molecules to T-cell receptors and the subsequent activation of B-cells to produce neutralizing antibodies.